Sulfasalazine, a specific inhibitor of xCT and FDA-approved drug, is a potent suppressor of tumors that inhibits growth, invasion, and metastasis as has been revealed by the attenuation or suppression of lymphoma growth (231), metastasis of melanocytes (235), proliferation, colony formation, metastasis and invasion of gastric cancer cells (236), and stemness and metastasis of colorectal cancer (237). Here, SLC7A11 is linked to gastric cancer.